# colorectal cancer - minimax-m3

- Benchmark system: raw
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3761
- Completion tokens: 9363
- Reasoning tokens: 
- Total tokens: 13124
- API requests reported: 
- Elapsed seconds: 51.422
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: MiniMax

---
<think>Let me carefully analyze this prognostic dataset for colorectal cancer (CRC) overall survival. The dataset contains genes with hazard ratios (HR), p-values, and FDR values. I need to interpret this in terms of biological programs, key genes, and validation priorities.

Let me first organize the data:

**Risk-associated genes (HR > 1, associated with worse OS):**
- INHBB (HR=1.43, p=2.0e-08) - Inhibin beta B, TGF-β superfamily
- SCARA3 (HR=1.38, p=8.9e-08) - Scavenger receptor
- MIR31HG (HR=1.31, p=4.2e-07) - lncRNA, linked to p16/CDKN2A
- ZEB1-AS1 (HR=1.37, p=9.8e-07) - lncRNA antisense to ZEB1 (EMT TF)
- DCBLD2 (HR=1.41, p=9.9e-07) - Discoidin domain receptor-related
- TPM4 (HR=1.36, p=1.3e-06) - Tropomyosin 4, cytoskeleton
- NPR3 (HR=1.35, p=3.3e-06) - Natriuretic peptide receptor
- LRRC8A (HR=1.38, p=8.0e-06) - Volume-regulated anion channel
- PTPN14 (HR=1.36, p=8.6e-06) - Protein tyrosine phosphatase, YAP regulator
- NIN (HR=1.35, p=1.7e-05) - Ninein, centrosomal
- ITGBL1 (HR=1.30, p=2.0e-05) - Integrin beta-like
- ABL2 (HR=1.30, p=1.4e-05) - Abelson kinase
- AKT3 (HR=1.32, p=3.6e-05) - AKT kinase 3, PI3K signaling
- NT5E (HR=1.31, p=4.3e-05) - CD73, adenosine production
- GJB6 (HR=1.29, p=4.0e-05) - Connexin 30, gap junction
- NAV3 (HR=1.26, p=4.1e-05) - Neuron navigator 3
- MAP1B (HR=1.33, p=6.7e-05) - Microtubule-associated protein
- BACE1 (HR=1.33, p=6.5e-05) - Beta-secretase
- FGF19 (HR=1.29, p=7.9e-05) - Fibroblast growth factor 19
- ADAMTS18 (HR=1.26, p=6.6e-05) - Metalloproteinase
- SLC2A3 (HR=1.28, p=1.5e-04) - GLUT3, glucose transporter
- GADD45B (HR=1.32, p=1.1e-04) - Growth arrest and DNA damage
- CYP1B1 (HR=1.29, p=1.1e-04) - Cytochrome P450
- MSLN (HR=1.31, p=6.1e-05) - Mesothelin
- FAM69C (HR=1.29, p=1.2e-04)

**Protective genes (HR < 1, associated with better OS):**
- ATP23 (HR=0.69, p=4.9e-07) - ATP23 peptidase
- NDUFA9 (HR=0.69, p=1.1e-06) - NADH dehydrogenase, Complex I
- SLC35G1 (HR=0.69, p=3.2e-06) - Solute carrier
- SH3RF2 (HR=0.73, p=4.9e-06) - SH3 domain
- TAPBPL (HR=0.71, p=4.9e-06) - TAP binding protein-like
- MYB (HR=0.77, p=5.3e-06) - Transcription factor (CRC: MYB is important in colon)
- GLYCTK (HR=0.71, p=6.0e-06) - Glycerate kinase
- CCDC134 (HR=0.71, p=9.9e-06)
- PPFIBP2 (HR=0.76, p=1.2e-05) - PTPRF interacting protein
- PXMP2 (HR=0.72, p=1.4e-05)
- MCCC2 (HR=0.74, p=1.5e-05) - Methylcrotonoyl-CoA carboxylase
- MYO5B (HR=0.75, p=1.6e-05) - Myosin VB
- RAB11FIP4 (HR=0.74, p=2.2e-05)
- ILVBL (HR=0.72, p=2.3e-05)
- OGFOD2 (HR=0.72, p=2.6e-05)
- KIAA1671 (HR=0.74, p=2.6e-05)
- ASL (HR=0.74, p=2.8e-05) - Argininosuccinate lyase, urea cycle
- CDX2 (HR=0.75, p=3.0e-05) - Caudal type homeobox 2 - KEY intestinal differentiation TF
- CCL15 (HR=0.75, p=3.0e-05) - Chemokine
- DNPEP (HR=0.73, p=3.1e-05) - Aspartyl aminopeptidase
- CS (HR=0.75, p=3.6e-05) - Citrate synthase, TCA cycle
- TIMM13 (HR=0.75, p=3.8e-05) - Mitochondrial import
- BCL2L14 (HR=0.76, p=4.1e-05) - Pro-apoptotic
- LGALS9 (HR=0.75, p=5.3e-05) - Galectin 9
- COA3 (HR=0.74, p=5.6e-05)
- LGALS4 (HR=0.77, p=7.8e-05) - Galectin 4 - intestinal epithelial
- ATP5G1 (HR=0.75, p=8.1e-05) - ATP synthase
- ATP5B (HR=0.75, p=9.9e-05) - ATP synthase
- DBI (HR=0.77, p=9.2e-05) - Diazepam binding inhibitor
- CDX1 (HR=0.78, p=9.3e-05) - Caudal type homeobox 1 - intestinal differentiation
- USP3 (HR=0.76, p=9.5e-05)
- ACSS2 (HR=0.76, p=1.0e-04) - Acetyl-CoA synthetase
- CNOT1 (HR=0.76, p=1.0e-04) - CCR4-NOT complex
- OGDHL (HR=0.69, p=1.5e-04) - Oxoglutarate dehydrogenase-like
- CASP6 (HR=0.77, p=6.2e-05) - Caspase 6, apoptotic
- GMNN (HR=0.76, p=1.3e-04) - Geminin, DNA replication
- METTL7B (HR=0.76, p=1.3e-04)
- AQP11 (HR=0.74, p=1.3e-04)
- NSMCE4A (HR=0.74, p=1.0e-04)

Now let me identify biological themes:

**Theme 1: EMT / Mesenchymal / Cytoskeletal remodeling (risk)**
- ZEB1-AS1 (lncRNA regulating ZEB1, master EMT TF)
- TPM4 (cytoskeletal, actin-binding)
- ITGBL1 (integrin-like, EMT-related)
- MAP1B (microtubule)
- NIN (centrosomal)
- ABL2 (cytoskeletal signaling)
- LRRC8A (cell volume/ion channel, can regulate EMT)

**Theme 2: Intestinal differentiation / Mucosal identity (protective)**
- CDX2 - master intestinal TF, key prognostic marker in CRC
- CDX1 - partner of CDX2
- LGALS4 - intestinal epithelial galectin
- MYO5B - intestinal epithelial polarity
- PPFIBP2 - cell adhesion
- SCEL - small intestine/late differentiation

**Theme 3: TGF-β / Growth factor signaling (risk)**
- INHBB - Activin B, TGF-β superfamily
- FGF19 - FGF signaling
- DCBLD2 - receptor tyrosine kinase-like
- GADD45B - stress response
- BACE1

**Theme 4: Metabolic reprogramming (mixed)**
Risk side: SLC2A3 (GLUT3, glycolysis), ACSS2 - actually protective
Protective: NDUFA9 (OXPHOS Complex I), OGDHL (TCA cycle), CS (TCA), ATP5B/G1 (OXPHOS), TIMM13 (mitochondrial import), MCCC2 (BCAA metabolism), GLYCTK, ASL (urea cycle), DBI
Risk: SLC2A3, CYP1B1 (drug metabolism)

This is interesting - the protective genes are enriched in mitochondrial metabolism/oxidative phosphorylation, while the risk side includes glycolytic transporter GLUT3.

**Theme 5: Immune microenvironment**
- LGALS9 (HR=0.75) - Galectin 9, TIM-3 ligand, immune checkpoint
- CCL15 (HR=0.75) - Chemokine
- NT5E (CD73, HR=1.31) - adenosine production, immunosuppressive

**Theme 6: Cell adhesion / Migration**
- DCBLD2, ITGBL1, MSLN, ADAMTS18

**Theme 7: Hippo / YAP pathway**
- PTPN14 - regulates YAP, can suppress YAP

Let me now think about which to prioritize as the top 5 biological programs:

1. **Intestinal differentiation identity (protective)** - CDX2, CDX1, MYO5B, LGALS4
   - These are all markers of mature intestinal epithelium
   - Loss associated with worse prognosis (CIMP, poor differentiation)

2. **EMT / Cytoskeletal remodeling (risk)** - ZEB1-AS1, TPM4, ITGBL1, MAP1B
   - Classic mesenchymal/EMT signature

3. **Mitochondrial OXPHOS / Metabolic differentiation (protective)** vs **Glycolytic shift (risk)**
   - NDUFA9, OGDHL, CS, ATP5B, ATP5G1 protective
   - SLC2A3 (GLUT3) risk
   - This is interesting - mitochondrial respiration may reflect better-differentiated cells

4. **TGF-β / Growth factor signaling (risk)** - INHBB, FGF19, NT5E
   - TGF-β family and growth factor signaling

5. **Immune modulation (mixed)** - NT5E (risk, immunosuppressive adenosine), LGALS9 (protective), CCL15 (protective)

Let me consider key genes more carefully:

**CDX2** (HR=0.75): Master intestinal TF. Loss of CDX2 is a well-established poor prognostic marker in CRC. This is a strong finding.

**ZEB1-AS1** (HR=1.37): lncRNA regulating ZEB1, master EMT TF. Strong link to EMT and metastasis.

**MIR31HG** (HR=1.31): lncRNA near CDKN2A/p16, has been associated with poor prognosis in CRC.

**INHBB** (HR=1.43): Activin B, TGF-β superfamily, can promote invasion.

**NT5E/CD73** (HR=1.31): Adenosine production, immunosuppressive TME.

**AKT3** (HR=1.32): PI3K signaling.

**PTPN14** (HR=1.36): Hippo/YAP regulator.

**MYB** (HR=0.77): Transcription factor, important in colon stem/progenitor cells.

Now let me consider the gene-gene interaction modules:

1. **CDX2-CDX1-LGALS4-MYO5B** - Intestinal differentiation module
2. **ZEB1-AS1-ZEB1** - EMT module
3. **INHBB-FGF19-DCBLD2** - Growth factor signaling
4. **NDUFA9-OGDHL-CS-ATP5B-ATP5G1** - OXPHOS module
5. **NT5E-LGALS9** - Adenosine/galectin immune checkpoint

Let me think about validation priorities:

1. **CDX2 as prognostic biomarker** - well-established, validate combined score
2. **EMT score (ZEB1-AS1, TPM4, ITGBL1)** - therapeutic target for EMT
3. **OXPHOS/metabolic signature** - therapeutic target (e.g., mitochondrial inhibitors)
4. **NT5E-CD73 axis** - therapeutic target (CD73 inhibitors exist)
5. **MIR31HG/ZEB1-AS1 axis** - lncRNA biomarker

Let me draft the response now. I'll structure it according to the requirements.

Actually, let me reconsider the metabolic theme. The protective genes:
- NDUFA9 (Complex I)
- OGDHL (TCA cycle)
- CS (Citrate synthase, TCA cycle)
- ATP5G1, ATP5B (ATP synthase)
- TIMM13 (mitochondrial import)
- MCCC2 (BCAA catabolism)
- GLYCTK (glycerate metabolism)
- ACSS2 (acetyl-CoA, acetate metabolism)
- ASL (urea cycle)
- DBI (acyl-CoA binding)
- PXMP2 (peroxisomal)
- ILVBL (acetolactate)
- OGFOD2

The risk side metabolic:
- SLC2A3 (GLUT3 - glucose transporter)
- CYP1B1 (drug metabolism, often overexpressed in cancer)

This pattern suggests that tumors retaining mitochondrial OXPHOS capacity are less aggressive, while those shifting to glycolysis (with GLUT3 upregulation) are more aggressive. This is consistent with the "Warburg effect" interpretation in reverse - tumors that escape the Warburg shift have better prognosis.

Note: This is somewhat counterintuitive because OXPHOS is often associated with cancer. But in CRC context, loss of differentiation often goes with loss of mature enterocyte metabolism features.

Let me also note INHBB - this is a notable finding. Inhibin beta B forms Activin B, which signals through SMAD2/3. In CRC, Activin signaling has been associated with poor prognosis, EMT, and chemoresistance.

Let me check the strongest signal: INHBB at HR=1.43, p=2e-08 is the strongest individual signal. This is consistent with Activin signaling being pro-tumorigenic in CRC.

OK let me also think about whether some of the protective genes might represent housekeeping/structural genes (like NDUFA9, ATP5B) - if these are simply reflecting tumor cell differentiation status, they may be prognostic mainly because they indicate a more differentiated state.

Let me think about the limitations:
1. Most genes have moderate HRs (1.2-1.4 range), suggesting many genes of small individual effect
2. No information on tumor stage, MSI status, CMS subtype, location (left vs right)
3. No information on treatment
4. Probe-level analysis suggests microarray platform, possibly older study
5. Some probes (PROBE_*) may represent poorly annotated transcripts
6. HR estimates from Cox models not detailed here - what covariates?
7. Multiple testing burden

Now I'll write the response.

Let me think about what is unique to this dataset. The top genes:

INHBB (HR=1.43) - this is the strongest. Activin signaling in CRC.
SCARA3 (HR=1.38) - scavenger receptor, less commonly cited
MIR31HG (HR=1.31) - p16 locus lncRNA, associated with poor CRC prognosis
ZEB1-AS1 (HR=1.37) - EMT lncRNA
DCBLD2 (HR=1.41) - receptor tyrosine kinase, neuropilin-like, linked to EMT/invasion

The protective:
CDX2 (HR=0.75) - well-known CRC differentiation marker, prognostic
CDX1 (HR=0.78) - CDX2 partner
MYO5B (HR=0.75) - microvillar inclusion disease gene, intestinal epithelial polarity
LGALS4 (HR=0.77) - intestinal galectin
MYB (HR=0.77) - colon stem cell TF
LGALS9 (HR=0.75) - immune checkpoint ligand

Now I'll draft a comprehensive response.

Actually, looking at the data more carefully, I want to make sure I capture the most important features:

For the metabolic theme, the enrichment of mitochondrial genes (NDUFA9, OGDHL, CS, ATP5G1, ATP5B, TIMM13) among protective genes is notable. This may reflect:
1. Better-differentiated enterocytes have high mitochondrial content
2. Tumors retaining OXPHOS are less glycolytic/aggressive
3. Or it may reflect tumor purity (mitochondrial genes correlate with stromal/immune content)

The risk side has SLC2A3 (GLUT3), suggesting glycolytic shift.

Let me finalize my response now. I'll aim for comprehensive but not excessive length. The key programs I'll identify are:

1. EMT / Mesenchymal identity (risk)
2. Intestinal epithelial differentiation (protective)
3. TGF-β / Activin signaling (risk)
4. Mitochondrial metabolism / OXPHOS (protective)
5. Immune microenvironment (mixed - CD73/Adenosine risk, Galectin 9/CCL15 protective)

Key genes to highlight:
- INHBB (Activin B)
- ZEB1-AS1 (EMT)
- MIR31HG (cell cycle/CDKN2A)
- CDX2 (intestinal differentiation)
- CDX1 (intestinal differentiation)
- NT5E/CD73 (adenosine)
- AKT3 (PI3K)
- PTPN14 (Hippo/YAP)
- LGALS9 (immune checkpoint)
- DCBLD2 (growth signaling)

Validation priorities:
1. CDX2-CD73 combined biomarker (Mechanistic/biomarker)
2. ZEB1-AS1/MIR31HG EMT score (Biomarker)
3. INHBB/Activin signaling therapeutic target (Therapeutic)
4. OXPHOS score metabolic vulnerability (Therapeutic/biomarker)
5. CD73-ADO axis therapeutic (Therapeutic target)

Now let me write the final response.</think>

# Multidimensional Interpretation of Prognostic Transcriptomic Signatures in Colorectal Cancer

## 1. Overall Biological Interpretation

This Cox regression–derived prognostic signature from colorectal tumor tissue points toward a **two-axis biology of poor prognosis**:

- An **EMT / mesenchymal / TGF-β–growth factor / glycolytic-shift axis** that stratifies tumors toward worse overall survival.
- A **conserved intestinal epithelial differentiation / mitochondrial OXPHOS / mucosal identity axis** that stratifies tumors toward better overall survival.

The signal is distributed across many moderate-effect genes (HRs typically 1.20–1.40 or 0.70–0.80), suggesting that survival biology in this cohort is governed by a **polygenic composite phenotype**, not by a single dominant driver. The strongest individual signal (INHBB, HR ≈ 1.43, p ≈ 2 × 10⁻⁸) implicates Activin/TGF-β signaling as a particularly influential risk component, while the most biologically coherent protective signals are anchored by the intestinal master regulator **CDX2**.

Conceptually, the dataset resembles a contrast between **dedifferentiated, mesenchymal, growth-factor–driven, glycolytic tumors** (poor prognosis) and **well-differentiated, intestinal identity–preserved, OXPHOS-competent tumors** (good prognosis), with an additional layer of **immune-metabolic checkpoint remodeling (adenosine/LGALS9)** overlaying both axes.

---

## 2. Core Biological Programs

### Program 1 — EMT, Cytoskeletal Remodeling, and Mesenchymal Identity (RISK)

- **Direction:** Risk-associated (HR > 1)
- **Major supporting genes:** ZEB1-AS1 (HR 1.37), TPM4 (1.36), ITGBL1 (1.30), MAP1B (1.33), NIN (1.35), ABL2 (1.30), LRRC8A (1.38), DCBLD2 (1.41)
- **Standard pathway:** Hallmark *Epithelial–Mesenchymal Transition*; Reactome *RHO GTPase signaling / Integrin signaling*
- **Why this program:** ZEB1-AS1 is a cis-regulatory lncRNA of ZEB1, the canonical EMT transcription factor. TPM4 and MAP1B are direct cytoskeletal effectors of mesenchymal migration; ITGBL1 is a TGF-β–induced integrin-like EMT protein; ABL2 couples cytoskeletal dynamics to growth-factor signaling. NIN (centrosomal) and LRRC8A (volume-regulated anion channel) are functionally linked to cell-shape change and migration. Together they constitute a coherent mesenchymal/migratory module rather than a list of unrelated hits.
- **Evidence strength:** Moderate–strong at the gene level (multiple independent cytoskeletal/EMT effectors all directional in the same direction); pathway-level coherence is high. **Limitations:** No EMT master TFs (SNAI1, SNAI2, ZEB1, TWIST1) appear themselves — the signal is at the *effector* layer, which is informative but indirect; this may reflect probe coverage or stage-specific EMT state.

### Program 2 — TGF-β / Activin / FGF Growth-Factor Signaling (RISK)

- **Direction:** Risk-associated
- **Major supporting genes:** INHBB (HR 1.43, p ≈ 2 × 10⁻⁸), FGF19 (1.29), DCBLD2 (1.41), GADD45B (1.32), BACE1 (1.33)
- **Standard pathway:** KEGG *TGF-β signaling pathway*; Reactome *Signaling by Activin / FGF19 signaling*
- **Why this program:** INHBB (Inhibin βB) dimerizes to form Activin B, which signals via SMAD2/3 and drives proliferation, EMT, and stemness in colon epithelium. FGF19 engages FGFR4–β-klotho, known to promote CRC proliferation and Wnt/β-catenin cross-talk. DCBLD2 is a receptor-type molecule induced by growth-factor stress and is a known YAP/TAZ-amplified invasion gene. GADD45B reflects genotoxic-stress-coupled growth arrest escape. The convergence on a TGF-β/FGF/RTK signaling triad with the same prognostic direction is internally consistent.
- **Evidence strength:** Strong for INHBB as an individual signal; supported by co-directionality of multiple TGF-β/RTK-adjacent genes. **Limitations:** No direct measurement of SMAD2/3 phosphorylation or ligand secretion; the dataset shows mRNA abundance, not signaling activity.

### Program 3 — Intestinal Epithelial Differentiation and Mucosal Identity (PROTECTIVE)

- **Direction:** Protective (HR < 1)
- **Major supporting genes:** CDX2 (HR 0.75), CDX1 (0.78), MYO5B (0.75), LGALS4 (0.77), SCEL (1.25* but directionally relevant for terminal differentiation*), PPFIBP2 (0.76)
- **Standard pathway:** GO *Intestinal epithelial cell differentiation*; Reactome *CDX2-regulated transcription*
- **Why this program:** CDX2 and CDX1 are the master homeobox transcription factors specifying intestinal epithelium; their loss is the textbook molecular signature of undifferentiated/poorly differentiated CRC and is independently prognostic. MYO5B maintains apical enterocyte polarity (its loss causes microvillus inclusion disease). LGALS4 is an intestinal-epithelium-restricted galectin whose expression tracks enterocyte differentiation. The joint directionality of all four is a strong, internally coherent differentiation signature.
- **Evidence strength:** Very strong — CDX2 in CRC is one of the most consistently validated prognostic biomarkers in the literature. **Limitations:** Some apparent "protective" genes in this list (e.g., MYO5B) may be partially confounded with non-malignant epithelial content; tumor-purity composition effects should be considered (see §6).

### Program 4 — Mitochondrial OXPHOS / Mature Enterocyte Metabolism (PROTECTIVE)

- **Direction:** Protective
- **Major supporting genes:** NDUFA9 (HR 0.69), OGDHL (0.69), CS (0.75), ATP5G1 (0.75), ATP5B (0.75), TIMM13 (0.75), MCCC2 (0.74), GLYCTK (0.71), ACSS2 (0.76), DBI (0.77), ASL (0.74)
- **Standard pathway:** Reactome *Respiratory electron transport / TCA cycle*; KEGG *Oxidative phosphorylation*
- **Why this program:** NDUFA9 is Complex I; OGDHL is the TCA cycle 2-oxoglutarate dehydrogenase; CS is citrate synthase; ATP5B/G1 are the F₁F₀-ATP synthase c-subunit; TIMM13 is a mitochondrial inner-membrane translocase. Together, these represent a strikingly consistent OXPHOS/TCA module moving in the same prognostic direction. In contrast, SLC2A3 (GLUT3) — the **glycolytic glucose transporter** — is on the risk side (HR 1.28), providing the mirror-image metabolic signal.
- **Evidence strength:** Strong — the directional coherence of OXPHOS genes is unusual and unlikely to be random. **Limitations:** A non-trivial alternative explanation is that OXPHOS transcripts partly reflect stromal/immune or normal-mucosa content rather than tumor-intrinsic biology (see §6).

### Program 5 — Immune-Metabolic Checkpoint and Adenosine Signaling (MIXED, with net RISK contribution)

- **Direction:** Mixed; net risk effect driven by immunosuppressive adenosine axis
- **Major supporting genes:** NT5E (CD73, HR 1.31), LGALS9 (HR 0.75), CCL15-CCL14/CCL15 (HR 0.75)
- **Standard pathway:** Reactome *Purinergic signaling / Adenosine signaling*; Hallmark *Inflammatory response*
- **Why this program:** NT5E/CD73 is the rate-limiting ecto-enzyme that converts extracellular AMP → adenosine, generating an immunosuppressive tumor microenvironment via A2A/A2B receptor signaling on T cells. Its risk association is biologically expected. LGALS9 is the ligand for the TIM-3 immune checkpoint; its *protective* direction is more nuanced — it can deliver inhibitory signals to TIM-3⁺ exhausted T cells (immunosuppressive) **or** be secreted and act as an alarmin, depending on context. CCL15 is a neutrophil/chemoattractant chemokine whose loss is paradoxically poor-prognosis in some CRC cohorts, possibly reflecting loss of mucosal immune surveillance.
- **Evidence strength:** Moderate for NT5E; weaker and more interpretively ambiguous for LGALS9/CCL15. **Limitations:** Direction of LGALS9 is not unambiguous in the literature — should not be over-interpreted without cellular source information (tumor vs. immune cell).

---

## 3. Key Genes and Interaction Modules

| # | Gene | Direction (HR) | Role | Relationship type |
|---|------|----------------|------|--------------------|
| 1 | **INHBB** | Risk, 1.43 | Activin B ligand — TGF-β superfamily | Pathway co-membership (Activin/SMAD) with DCBLD2/FGF19; potential regulatory on ZEB1-AS1 via SMAD-driven EMT |
| 2 | **ZEB1-AS1** | Risk, 1.37 | lncRNA cis-acting on ZEB1 (EMT TF) | Putative regulatory; co-expression with TPM4/ITGBL1 (EMT effectors) — *not* direct physical interaction |
| 3 | **MIR31HG** | Risk, 1.31 | lncRNA in the CDKN2A/p16 locus; chromatin regulator | Co-expression / locus co-regulation with CDKN2A; regulatory on cell-cycle and EMT programs |
| 4 | **CDX2** | Protective, 0.75 | Master intestinal TF | Direct transcriptional regulation of CDX1, LGALS4, MYO5B; co-expression with mitochondrial-gene signature of mature enterocytes |
| 5 | **CDX1** | Protective, 0.78 | Intestinal TF; CDX2 partner | Co-expression with CDX2 (functional partnership); pathway co-membership in intestinal differentiation |
| 6 | **NT5E (CD73)** | Risk, 1.31 | Adenosine-generating ecto-enzyme | Pathway co-membership in purinergic signaling; functional antagonism with LGALS9-mediated immune effects |
| 7 | **DCBLD2** | Risk, 1.41 | Neuropilin-like receptor; invasion/RTK-related | Co-expression with INHBB/FGF19 (growth-factor module); pathway co-membership |
| 8 | **AKT3** | Risk, 1.32 | PI3K/AKT effector isoform | Pathway co-membership with EMT/invasion programs; co-expression with PTPN14 in Hippo-cross-talk context |
| 9 | **PTPN14** | Risk, 1.36 | Hippo pathway / YAP regulator; protein tyrosine phosphatase | Direct regulatory interaction with YAP (well-established); co-expression with cytoskeletal EMT effectors |
| 10 | **SLC2A3 (GLUT3)** | Risk, 1.28 | High-affinity glucose transporter; glycolytic shift | Functionally inverse to NDUFA9/OGDHL/CS/ATP5B OXPHOS module (metabolic re-programming) |

**Module summary:**
- **EMT-effector module:** ZEB1-AS1 ↔ TPM4 / MAP1B / ITGBL1 / ABL2 — *co-expression and pathway co-membership*, not direct physical interaction.
- **Intestinal identity module:** CDX2 → CDX1 → LGALS4 / MYO5B — *direct transcriptional regulation and co-expression* (CDX2 directly transactivates CDX1 and many intestinal differentiation genes).
- **OXPHOS / glycolysis metabolic dichotomy:** NDUFA9 + OGDHL + CS + ATP5B/G1 ↔ SLC2A3 — *functional/metabolic antagonism*, not direct interaction.
- **Growth-factor/Hippo module:** INHBB + FGF19 + DCBLD2 ↔ PTPN14 — *pathway co-membership and putative cross-talk*; no direct interaction established from this dataset.

---

## 4. Validation Priorities

### Priority 1 — CDX2-centered intestinal differentiation score (Biomarker / Confounding check)

- **Why prioritize:** CDX2 loss is already a validated prognostic marker in CRC. The current dataset confirms its protective direction and shows it co-moves with CDX1, LGALS4, MYO5B, and OXPHOS genes. This supports a composite "intestinal identity" score.
- **Evidence in dataset:** CDX2 HR 0.75, FDR ≈ 0.036; convergent signals from CDX1, LGALS4, MYO5B.
- **External evidence:** Strong — multiple IHC-based studies show CDX2 loss as an independent prognostic factor in stage II/III CRC.
- **Next step:** Build a CDX2/CDX1/LGALS4/MYO5B four-gene qPCR or IHC score and test in an independent cohort with MSI and CMS subtype annotation.
- **Status:** **Supported hypothesis** (likely Established evidence at the single-gene level; Supported at the composite-score level).

### Priority 2 — ZEB1-AS1 / MIR31HG EMT-lncRNA panel (Biomarker)

- **Why prioritize:** Two independent lncRNAs on the risk side point to EMT regulation at the *epigenetic/post-transcriptional* layer, complementing the EMT-effector protein signature.
- **Evidence in dataset:** ZEB1-AS1 HR 1.37, FDR ≈ 0.009; MIR31HG HR 1.31, FDR ≈ 0.007. Both co-move with TPM4/MAP1B/ITGBL1.
- **External evidence:** MIR31HG is published as a poor-prognosis marker in CRC; ZEB1-AS1 has been linked to EMT in multiple cancer types but less studied in CRC.
- **Next step:** Validate by RT-qPCR in FFPE CRC cohorts stratified by EMT status; assess correlation with ZEB1 protein.
- **Status:** **Supported hypothesis** (single lncRNAs); **Exploratory hypothesis** (composite score).

### Priority 3 — INHBB / Activin B signaling as a therapeutic vulnerability (Therapeutic target / Mechanistic hypothesis)

- **Why prioritize:** INHBB is the strongest individual prognostic gene (HR 1.43, FDR ≈ 0.001), the dataset is internally consistent with TGF-β-family growth-factor biology, and Activin/TGF-β signaling is pharmacologically tractable.
- **Evidence in dataset:** Top-ranking risk gene, converges with FGF19 and DCBLD2 directionally.
- **External evidence:** Activin signaling promotes CRC proliferation, EMT, and chemoresistance; INHBB overexpression is reported in aggressive CRC.
- **Next step:** Assess Activin receptor (ACVR1B/ACVR2A) expression by IHC; test whether INHBB-high tumors are sensitive to TGF-β receptor / Activin pathway inhibitors in organoid or xenograft models.
- **Status:** **Supported hypothesis** (clinical association); **Exploratory hypothesis** (therapeutic vulnerability — no clinical evidence yet that targeting Activin benefits CRC patients).

### Priority 4 — CD73 (NT5E) / adenosine-axis therapeutic target (Therapeutic target)

- **Why prioritize:** CD73 is the rate-limiting adenosine-generating enzyme and an established druggable immune checkpoint with multiple clinical-stage inhibitors (e.g., oleclumab).
- **Evidence in dataset:** NT5E HR 1.31, FDR ≈ 0.04 — modest but directionally consistent with a large external literature.
- **External evidence:** Strong — CD73 is a clinically validated target in non-small-cell lung cancer; preclinical CRC data support its role in immune evasion.
- **Next step:** Examine NT5E expression in relation to tumor-infiltrating CD8⁺ T cells and CMS1 (MSI-immune) tumors; assess whether NT5E-high tumors co-express LGALS9/TIM-3 (a therapeutically actionable combination).
- **Status:** **Supported hypothesis** for prognostic value; **Exploratory hypothesis** for therapeutic benefit specifically in CRC.

### Priority 5 — OXPHOS / glycolytic-shift metabolic signature (Mechanistic hypothesis / Biomarker)

- **Why prioritize:** An unusual, internally coherent cluster of mitochondrial genes (NDUFA9, OGDHL, CS, ATP5G1, ATP5B, TIMM13) all protectively prognostic, opposite to SLC2A3 (GLUT3). This reciprocal metabolic signature is a candidate mechanistic biomarker and therapeutic vulnerability layer.
- **Evidence in dataset:** Six+ mitochondrial genes with HR ≈ 0.69–0.77, FDR < 0.05; SLC2A3 risk-side (HR 1.28).
- **External evidence:** Partial — OXPHOS in CRC is context-dependent (progenitor-like CSCs are OXPHOS-low); glycolytic gene signatures are prognostic in multiple CRC cohorts.
- **Next step:** Test whether the protective OXPHOS signature reflects (a) tumor-intrinsic differentiation or (b) stromal/normal epithelial contamination by performing tumor-purity-adjusted analyses (ESTIMATE, IHC for tumor cellularity). If tumor-intrinsic, OXPHOS-high tumors may be uniquely sensitive to mitochondrial inhibitors (e.g., IACS-010759).
- **Status:** **Supported hypothesis** (prognostic); **Exploratory hypothesis** (mechanism: intrinsic vs. compositional; therapeutic).

---

## 5. Evidence Grounding Summary

| Program / Gene | Direct dataset evidence | Pathway/ontology evidence | Protein interaction / regulatory | Disease-association evidence | Expression/tissue evidence | Drug evidence |
|---|---|---|---|---|---|---|
| EMT (ZEB1-AS1, TPM4, ITGBL1) | HR>1, FDR<0.05 | Hallmark EMT | Indirect (ZEB1 regulatory axis) | CRC EMT literature | Stromal/mesenchymal patterns | EMT-targeting drugs in development |
| TGF-β (INHBB, FGF19, DCBLD2) | Strongest signal INHBB | KEGG TGF-β | SMAD-pathway cross-talk | CRC Activin/FGF19 literature | Activin B in CRC tissue | TGF-β pathway inhibitors |
| Intestinal differentiation (CDX2/CDX1) | HR<1, FDR<0.05 | GO intestinal differentiation | CDX2→CDX1 direct regulation | Established CRC prognostic | Strong intestinal-restricted | None specific |
| OXPHOS (NDUFA9/CS/ATP5B) | Multiple genes HR<1 | Reactome OXPHOS | None direct | Partial (context-dependent) | Mitochondrial tissue markers | Mitochondrial inhibitors (IACS-010759) |
| Immune-metabolic (NT5E, LGALS9) | Mixed direction | Reactome purinergic | NT5E→adenosine established | CD73 in lung cancer; LGALS9 ambiguous | Stromal/immune | CD73 inhibitors (oleclumab) |

**Independence of evidence sources:** For the EMT program, the dataset evidence, Hallmark-pathway annotation, and CRC disease-association literature are largely *non-independent* (they draw on overlapping published CRC EMT studies). For the CDX2 program, dataset evidence and external CRC prognostic evidence are *genuinely independent* (the dataset was not the source of CDX2's established role). For the OXPHOS program, the multiple-gene concordance within the dataset is genuinely independent of any single prior literature claim and is therefore a *cohort-internal* signal of moderate originality.

**Conflicts:** LGALS9's protective direction in this dataset conflicts with portions of the cancer-immunology literature where LGALS9–TIM-3 interactions are interpreted as immunosuppressive (and therefore risk). This conflict is plausibly explained by LGALS9 having context-dependent roles and by cellular-source heterogeneity (tumor vs. immune cells), which the bulk-tissue dataset cannot resolve.

---

## 6. Limitations and Alternative Explanations

### 1. Tumor purity and stromal / normal-epithelial contamination
The OXPHOS cluster (NDUFA9, CS, ATP5G1, ATP5B) and the intestinal-differentiation cluster (CDX2, CDX1, LGALS4, MYO5B) may be partly **confounded with tumor cellularity**: better-prognosis tumors may simply contain more normal mucosa / better-differentiated tumor cells expressing these lineage markers, while poor-prognosis undifferentiated tumors have lower expression because of fewer mature enterocytes per tumor cell. **How to investigate:** ESTIMATE / MCP-counter tumor-purity adjustment; paired bulk + single-cell or spatial transcriptomics.

### 2. Tissue-composition differences (left vs. right colon; MSI vs. MSS)
CDX2 expression is markedly higher in left-sided CRC and in MSS tumors; SL
C2A3 and EMT programs are enriched in right-sided and MSI-H tumors respectively. Without stage, location, MSI, and CMS annotation, the prognostic signal cannot be cleanly separated from these confounded molecular subtypes.

### 3. Treatment exposure
No information on adjuvant chemotherapy, surgery type, or targeted therapy is implied by the table. INHBB and CD73 signals in particular may be modulated by treatment; the prognostic HR estimates may partly reflect treatment response rather than intrinsic biology.

### 4. Broad / non-specific pathway enrichment
Many of the protective genes are housekeeping (mitochondrial OXPHOS, ATP synthase, mitochondrial import). Their coordinated protective effect may partly reflect a **generic "cellular health / metabolic competence"** signal rather than a CRC-specific pathway. This warrants cross-checking in non-CRC datasets to ensure the signal is disease-specific.

### 5. Association-versus-causation ambiguity
All findings are statistical associations from a Cox model. In particular, INHBB, ZEB1-AS1, and CDX2 are **prognostic markers** whose causal contribution to mortality has not been demonstrated here. For example, ZEB1-AS1 may mark aggressive disease rather than *cause* it; CDX2 may mark indolent well-differentiated disease rather than actively suppress metastasis.

### 6. Platform / probe ambiguity
Several rows are probe-level identifiers (PROBE_*), some gene names are concatenated (LOC101928747|RBMX|SNORD61, MSANTD3-TMEFF1|TMEFF1, MIR1248|SNORA81|…), suggesting microarray platform and possible ambiguous transcript assignment. This limits confidence in those specific gene assignments.

### 7. Moderate effect sizes
The vast majority of HRs lie between 1.20–1.40 (risk) or 0.70–0.80 (protective). No single gene is overwhelmingly prognostic; the signature is genuinely polygenic, which limits the value of any single-gene biomarker interpretation.

---

## Summary Statement

This dataset defines a **multi-axis prognostic landscape in colorectal cancer**: risk-associated programs converge on **TGF-β/Activin signaling (INHBB), EMT effectors (ZEB1-AS1, TPM4, ITGBL1), and glycolytic shift (SLC2A3)**, while protective programs reflect **conserved intestinal differentiation (CDX2, CDX1, LGALS4, MYO5B)** and **mitochondrial OXPHOS competence (NDUFA9, OGDHL, CS, ATP5B, ATP5G1)**, overlaid by an **adenosine/LGALS9 immune-checkpoint layer (NT5E risk; LGALS9 ambiguous)**. The findings are **internally coherent** but require **independent validation with MSI, CMS, stage, and tumor-purity annotation** to distinguish tumor-intrinsic biology from compositional confounding. The most actionable immediate priorities are **(i) a CDX2/CDX1-based intestinal-identity score**, **(ii) an Activin/INHBB mechanistic / therapeutic exploration**, and **(iii) a CD73–LGALS9 immune-checkpoint biomarker–target combination**, all of which warrant confirmation in molecularly annotated independent cohorts.
